Stockscreener 앱 받기
34.41
0.20%
-0.07
시간 외 거래:
34.41
전일 마감가:
$34.48
열려 있는:
$34
하루 거래량:
504.75K
Relative Volume:
0.70
시가총액:
$1.28B
수익:
$272.30M
순이익/손실:
$-5.14M
주가수익비율:
-210.46
EPS:
-0.1635
순현금흐름:
$42.76M
1주 성능:
-3.23%
1개월 성능:
-32.29%
6개월 성능:
-22.40%
1년 성능:
+26.14%
1일 변동 폭
$33.53
$34.78
1주일 범위
$33.53
$36.15
52주 변동 폭
$20.85
$54.85
Harrow Inc Stock (HROW) Company Profile
명칭
Harrow Inc
전화
615.733.4731
주소
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
34.41 | 1.28B | 272.30M | -5.14M | 42.76M | -0.1635 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 개시 | BTIG Research | Buy |
| 2025-06-10 | 개시 | William Blair | Outperform |
| 2025-02-06 | 개시 | H.C. Wainwright | Buy |
| 2024-12-04 | 재확인 | B. Riley Securities | Buy |
| 2024-04-11 | 개시 | Craig Hallum | Buy |
| 2022-09-08 | 재개 | B. Riley Securities | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2021-09-24 | 개시 | Aegis Capital | Buy |
| 2021-07-02 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Harrow Inc 주식(HROW)의 최신 뉴스
HROW: Analyst HC Wainwright & Co. Reiterates 'Buy' with $70 Targ - GuruFocus
Harrow's (HROW) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Nomura Downgrades Harrow Health, Inc. (HROW) to Neutral March 18, 2026 - Meyka
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting - Bitget
Harrow outlines $350M–$365M 2026 revenue goal as sales force expansion and pipeline advances fuel momentum - MSN
HROW: BTIG Reiterates Buy Rating with $63 Price Target | HROW St - GuruFocus
Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research - MarketBeat
Penn Capital Management Company LLC Makes New Investment in Harrow, Inc. $HROW - MarketBeat
Eye drug studies on dry eye and cataract surgery headed to DC stage - Stock Titan
EnerQuest expansion in Essex County to bring jobs, shift production from U.S. - CBC
Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market (NASDAQ:HROW) - Seeking Alpha
Cantor Fitzgerald Initiates Coverage of Harrow (HROW) with Overweight Recommendation - MSN
EnerQuest in Harrow gets support for re-shoring manufacturing - Sarnia News Today
307,337 Shares in Harrow, Inc. $HROW Bought by Luxor Capital Group LP - MarketBeat
Harrow: why this fast-growing eye-care pharma stock is worth a look - Finimize
Braidwell LP Decreases Stock Position in Harrow, Inc. $HROW - MarketBeat
Assessing Harrow (HROW) Valuation After Strong Revenue Growth And TRIESENCE Phase 3 Progress - Sahm
Harrow, Inc. (NASDAQ:HROW) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Harrow (HROW) Is Down 6.5% After Raising 2026 Guidance And Advancing TRIESENCE To Phase 3 - simplywall.st
Daniel Kaufman holds 1.878M Harrow shares (HROW) — 5.04% reported - Stock Titan
Harrow Health Projects Robust Growth After Strong 2025 - The Globe and Mail
Harrow Health at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com
Harrow (HROW) Q4 2025 Earnings Call Transcript - AOL.com
HROW: Record growth and expanding ophthalmic portfolio drive optimism for future launches - TradingView
Harrow (NASDAQ: HROW) furnishes March 2026 corporate investor presentation - Stock Titan
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions - Investing.com Canada
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Reven - GuruFocus
HARROW INCHROW 8 5/8 04/30/26 (HROWL) Earnings History & Surprises - ChartMill
Is Harrow Inc. stock a top pick in earnings seasonTrade Performance Summary & Safe Entry Point Alerts - Naître et grandir
Harrow, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:HROW) 2026-03-06 - Seeking Alpha
Has The Recent Slide In Harrow (HROW) Opened A Valuation Opportunity For Investors - simplywall.st
HC Wainwright Issues Negative Forecast for Harrow Earnings - MarketBeat
Buy or Sell Harrow Stock? - Trefis
A Look At Harrow (HROW) Valuation After Mixed Q4 Results And 2026 Profitability Concerns - Yahoo Finance
A Look At Harrow (HROW) Valuation After Q4 2025 Earnings Miss And Raised 2026 Spending Plans - simplywall.st
HC Wainwright Has Pessimistic Outlook of Harrow Q3 Earnings - MarketBeat
Harrow (NASDAQ:HROW) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference - The Globe and Mail
H.C. Wainwright raises Harrow Health stock price target to $70 By Investing.com - Investing.com UK
Harrow stock stabilizes after major Tuesday drop - Nashville Post
Harrow Inc (HROW) Trading 4.78% Higher on Mar 4 - GuruFocus
Cantor Fitzgerald lowers Harrow Health stock price target to $91 - Investing.com
Cantor Fitzgerald Lowers Harrow (NASDAQ:HROW) Price Target to $91.00 - MarketBeat
These Analysts Revise Their Forecasts On Harrow Following Q4 Results - Benzinga
Harrow (HROW): Today's Analyst Rating and Price Target Update | - GuruFocus
Harrow (NASDAQ:HROW) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Harrow Health, Inc. (NASDAQ:HROW) Q4 2025 Earnings Call Transcript - Insider Monkey
HROW: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus
Does Harrow’s (HROW) TRIESENCE Cataract Trial Redefine Its Dropless Eye Care Strategy? - simplywall.st
H.C. Wainwright raises Harrow Health stock price target to $70 - Investing.com
Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade) (NASDAQ:HROW) - Seeking Alpha
Harrow Inc (HROW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):